Skip to main content
Premium Trial:

Request an Annual Quote

VolitionRx, Active Motif Ink Distribution Deal

NEW YORK (GenomeWeb News) – VolitionRx said today it has reached a deal with Active Motif to co-exclusively distribute VolitionRx's NuQ product line in Europe, the US, and Japan.

The NuQ products are based on VolitonRx's Nucleosomics platform for identifying and quantifying nucleosome structural features, such as histone modifications and variations, DNA methylation patterns, and nucleosome-protein adducts.

Financial and other terms of the deal were not disclosed.

"The NuQ ELISA kits that VolitionRx has developed are a perfect complement to our existing range of research tools for epigenetic analysis," Gary Shiels, director of global marketing at Active Motif, said in a statement. "The study of intact nucleosomes opens up a whole new set of options for the experiments that scientists can perform, moving closer to the natural environment in which epigenetic modifications and variations occur."

The NuQ product range currently consists of 15 immunoassays across four families, capturing intact nucleosomes and detecting specific features. In June, Volition raised $595,000 toward a targeted $1.5 million round to fund ongoing trials for its NuQ technology, and company CEO Cameron Reynolds said today that revenues from its research-use only kits will go toward funding of the trials.

"This partnership goes beyond just the distribution of our kits - Active Motif is a technology partner whose expertise in antibody development has assisted us in developing this unique line of products," VolitionRx Director of Sales and Marketing Thomas Bygott said. "In addition, they have an extensive network of highly specialist sales teams in the US, Japan, and across Europe that can help scientists choose the most suitable experiments for their needs, as well as a wide range of distributors across the world."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.